AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03081884
Drug: FACBC PET-CT Imaging
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection.
Trial: NCT00580801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
Trial: NCT01463384
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg, twice daily for 6 months.
Trial: NCT02128958
Drug: CF102
RxNorm normalized name: Cannabinoid Receptor Agonist CF102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12h
Trial: NCT02887313
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
Trial: NCT02128958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12 hours
Trial: NCT02565576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02565576
Drug: CFZ533
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00666406
Drug: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 50 +/- 5 IU/kg bodyweight
Trial: NCT00590603
Drug: Arsenic Trioxide, Ascorbic Acid and Bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I/Cohort I~Loading:~1. Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~2. Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~1. ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~2. Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~3. Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I.
Trial: NCT04528719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride (normal saline) injection
Trial: NCT00902512
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viagra® 100 mg tablet, administered with water single dose
Trial: NCT00921830
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
Trial: NCT00542386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
Trial: NCT00614406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet daily.
Trial: NCT00820118
Drug: Structured treatment interruption
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~* atazanavir : 300 mg/d~* ritonavir : 100 mg/d~* abacavir 600 mg and lamivudine 300 mg : once a day~* tenofovir 245 mg and emtricitabine 200 mg : once a day
Trial: NCT03784677
Drug: TRPV6 Calcium Channel Inhibitor SOR-C13
RxNorm normalized name: SOR-C13
DrugBank: SOR-C13 (DB15366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03643627
Drug: SYNT001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single IV infusion
Trial: NCT03643627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single IV infusion
Trial: NCT04511650
Drug: Placebo Subcutaneous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
Trial: NCT01044056
Drug: norelgestrominum and ethinylestradiol patch oral contraceptive patch
RxNorm normalized name: norelgestromin and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
Trial: NCT00859573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive substance
Trial: NCT00902512
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg CT administered with water single dose
Trial: NCT02392676
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Trial: NCT00946751
Drug: Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01565928
Drug: MDV3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 40 mg capsules, orally, once per day
Trial: NCT03009734
Drug: ATx201 dermal formulations 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of ATx201 dermal formulations 2%
Trial: NCT03914651
Drug: 300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
Trial: NCT03914651
Drug: 150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
Trial: NCT02440685
Drug: ASN002 RD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recommended dose of ASN002 from Part A
Trial: NCT01923948
Drug: Placebo (for Pregabalin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral dose of placebo given before surgery
Trial: NCT02971306
Drug: standard medical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
Trial: NCT02750319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02191852
Drug: Seresis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03597503
Drug: SPN-810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dose
Trial: NCT03597503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01451385
Drug: COV795
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)
Trial: NCT00994149
Drug: Ora-plus
RxNorm normalized name: Ora-Plus Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, give every 8 hours.
Trial: NCT01755325
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04227990
Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Trial: NCT03984812
Drug: GSK3732394
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL
Trial: NCT03984812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.
Trial: NCT00370799
Drug: Caudal Epidural Injection with generic Celestone
RxNorm normalized name: Celestone Soluspan Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
Trial: NCT00370799
Drug: Caudal Epidural Injection with Celestone
RxNorm normalized name: Celestone Soluspan Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
Trial: NCT00370799
Drug: Caudal Epidural Injection with DepoMedrol
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
Trial: NCT01738867
Drug: GSK1521498
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White HPMC capsule containing 10 mg of GSK1521498
Trial: NCT01337518
Drug: EZN-4176
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
Trial: NCT01738867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules to GSK1521498 or NTX
Trial: NCT01847690
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cortef 5 mg tablets per os, 2x5 mg, one day, one time
Trial: NCT04216706
Drug: tailored pharmaceutical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
Trial: NCT01887184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline was given
Trial: NCT01013090
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
Trial: NCT01959412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
Trial: NCT02338856
Drug: MB12066 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg bid (multiple dose, day 8)
Trial: NCT02338856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg bid (multiple dose, day 8)
Trial: NCT02624453
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
Trial: NCT02094729
Drug: BAN2401 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
Trial: NCT02094729
Drug: BAN2401 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
Trial: NCT02094729
Drug: BAN2401 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
Trial: NCT02094729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of placebo for 60 +/- 10 minutes.
Trial: NCT04236219
Drug: ALLN-346
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
Trial: NCT04236219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
Trial: NCT02386449
Drug: sodium picosulfate, magnesium oxide and citric acid (Picoprep®)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01758913
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
Trial: NCT02244229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00904904
Drug: Indomethacin ophthalmic solution
RxNorm normalized name: indomethacin Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
Trial: NCT00904904
Drug: Ketorolac Ophthalmic Solution
RxNorm normalized name: ketorolac Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
Trial: NCT04346329
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Group
Trial: NCT00604630
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
Trial: NCT01435486
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
Trial: NCT01435486
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with an equivalent volume of normal saline.
Trial: NCT01826448
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02588404
Drug: LHRH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These patients will be treated with LHRH agonist as standard therapy.
Trial: NCT02612922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally twice daily for five days
Trial: NCT00310596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,9% saline at 0,6mL/kg at bolus rate
Trial: NCT02671097
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
Trial: NCT03325595
Drug: AEF0117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2, 0.6, 2, or 6mg of AEF0117
Trial: NCT03325595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsule placebo
Trial: NCT00348673
Drug: UK-453,061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
Trial: NCT00348673
Drug: UK-453,061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
Trial: NCT01288001
Drug: Ostenil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Sodium Hyaluronate plus Mannitol injection
Trial: NCT03910088
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Giving drug to relieve post-dural puncture headache
Trial: NCT03910088
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: giving a drug to relieve post-dural puncture headache
Trial: NCT03910088
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: giving a drug to relieve post-dural puncture headache
Trial: NCT03910088
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: giving a drug to relieve post-dural puncture headache
Trial: NCT02197234
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
Trial: NCT02197234
Drug: AZD9291 tablet dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
Trial: NCT02820857
Drug: Folfiri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
Trial: NCT01037907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or 5 g dose
Trial: NCT01348386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04480658
Drug: Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe
Trial: NCT00475189
Drug: loestrin 24/4 vs loestrin 1/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
Trial: NCT00475189
Drug: loestrin 1/20
RxNorm normalized name: Loestrin 1/20 21 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
Trial: NCT02114489
Drug: ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unique perfusion of ibandronate 3 mg IV
Trial: NCT02114489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03058900
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly methotrexate in maximum tolerable dosis
Trial: NCT01986374
Drug: HCG is introduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: must have good blastocysts
Trial: NCT01584362
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of placebo
Trial: NCT03145259
Drug: Diclofenac Epolamine Patch
RxNorm normalized name: Diclofenac Epolamine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patch
Trial: NCT03145259
Drug: diclofenac sodium solution
RxNorm normalized name: Diclofenac Sodium Solution
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: solution
Trial: NCT02709330
Drug: Lunasin Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LunaRich X Capsules, Reliv Now, ProVantage
Trial: NCT04523883
Drug: JS001
RxNorm normalized name: Janus Kinase Inhibitor JS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 240mg every three week
Trial: NCT00040469
Drug: Campath -1H
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00040469
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes